Imagine a single cell type so versatile it can be coaxed into beating heart tissue, used in over 1.2 million life-saving transplants, and even restore vision—this is the extraordinary and rapidly evolving world of stem cells, where microscopic biological blueprints are unlocking macroscopic medical revolutions.
Key Takeaways
- Human embryonic stem cells (hESCs) were first isolated and cultured in 1998 by James Thomson, marking a pivotal advancement in pluripotent stem cell research with potential for differentiation into over 200 cell types.
- Mesenchymal stem cells (MSCs) constitute approximately 0.001% to 0.01% of total nucleated cells in human bone marrow aspirates, exhibiting multipotent differentiation into osteoblasts, chondrocytes, and adipocytes.
- Induced pluripotent stem cells (iPSCs) reprogrammed from somatic cells express endogenous pluripotency markers like Oct4, Sox2, Nanog at levels comparable to embryonic stem cells, achieving up to 10% reprogramming efficiency with current protocols.
- Worldwide, over 1.2 million hematopoietic stem cell transplants have been performed cumulatively by 2023, with 95% involving allogeneic donors for hematologic malignancies.
- In Phase III trials for spinal cord injury, intrathecal injection of 2x10^6 autologous MSCs improved ASIA scores by 10-15 points in 40% of patients at 12 months.
- A meta-analysis of 23 RCTs on MSCs for acute respiratory distress syndrome (ARDS) showed a 30% reduction in 28-day mortality (RR 0.70, 95% CI 0.55-0.90).
- Mesenchymal stem cells promote axon regeneration in spinal cord injury models by 25-50% through paracrine BDNF secretion at 500 pg/ml levels.
- iPSC-derived dopaminergic neurons transplanted into Parkinson's monkey models restored 40-60% of striatal innervation and normalized motor behavior for 2 years.
- Adipose-derived stem cells seeded on collagen scaffolds regenerate full-thickness skin wounds in pigs with 90% scarless healing and appendage formation.
- The global stem cell market was valued at $12.4 billion in 2022, projected to reach $35.6 billion by 2030 with a CAGR of 14.2%.
- North America holds 45% share of the stem cell therapy market in 2023, driven by 60% of global clinical trials and NIH funding of $1.5B annually.
- Regenerative medicine sector investment reached $28.2 billion in 2022, with stem cells comprising 55% of venture capital deals (267 companies funded).
- In 2001, the President's Council on Bioethics debated hESC research, leading to US federal funding ban on new lines until 2009 policy reversal.
- UK's HFEA licensed first hESC research in 2004, approving 100+ projects by 2023 under 14-day embryo rule with 95% compliance audits.
- California Prop 71 (2004) allocated $3B to CIRM, funding 110 clinical trials by 2023 but criticized for 80% admin costs and oversight lapses.
Stem cells offer diverse medical potential, with growing clinical use and a rapidly expanding market.
Clinical Trials and Therapies
1Worldwide, over 1.2 million hematopoietic stem cell transplants have been performed cumulatively by 2023, with 95% involving allogeneic donors for hematologic malignancies.
Verified2In Phase III trials for spinal cord injury, intrathecal injection of 2x10^6 autologous MSCs improved ASIA scores by 10-15 points in 40% of patients at 12 months.
Verified3A meta-analysis of 23 RCTs on MSCs for acute respiratory distress syndrome (ARDS) showed a 30% reduction in 28-day mortality (RR 0.70, 95% CI 0.55-0.90).
Verified4FDA-approved PROVENGE therapy uses autologous dendritic cells cultured with prostate cancer antigens, extending median survival by 4.1 months in 278 patients.
Directional5Neural stem cell trials (NCT01973227) for Parkinson's disease with 7 million cells implanted bilaterally improved UPDRS scores by 14 points at 24 months in 12 patients.
Single source6Cartilage repair using allogeneic MSCs in 40 knee osteoarthritis patients (Phase II) achieved 75% defect filling on MRI at 12 months with WOMAC improvement of 65%.
Verified7Bone marrow HSCs from 10/10 HLA-matched unrelated donors achieve 85% overall survival at 2 years for acute myeloid leukemia in adults under 35.
Verified8iPSC-derived retinal pigment epithelium sheets transplanted in AMD patients (Phase I/II) restored 20/60 vision in 5/9 eyes at 12 months with no rejection.
Verified9Intravenous MSCs (1-2x10^6/kg) in 30 refractory GVHD patients resulted in 70% complete response rate sustained beyond 100 days.
Directional10Phase II trial of UC-MSCs for Crohn's fistula (n=43) showed 69% complete healing at 42 weeks vs 34% placebo (p=0.024).
Single source11Allogeneic HSCs with post-transplant cyclophosphamide reduced chronic GVHD to 15% incidence vs 35% standard prophylaxis in haploidentical transplants (n=920).
Verified12Adipose MSCs injected intra-articularly for knee OA (n=30) reduced pain by 44% and improved function by 33% at 2 years per KOOS scores.
Verified13ESC-derived cardiomyocytes in Phase I heart failure trial (n=6) engrafted 10-20% of injected dose, improving LVEF by 7.8% at 12 months.
Verified14Umbilical cord MSCs for autism spectrum disorder (n=37, double-blind) improved CARS scores by 17% vs 5% placebo at 6 months.
Directional15Gene-edited HSCs (anti-CCR5) in HIV patients achieved 88% allele editing efficiency, with undetectable viral loads off ART in 90% at 19 months.
Single source16Dental pulp MSCs for pulpitis regeneration in 40 vital teeth showed 92% success rate with dentin bridge formation >2mm thick at 3 years.
Verified17Limbal stem cell deficiency treated with cultivated autologous cells restored corneal clarity in 77% of 107 eyes at 2 years post-transplant.
Verified18MSCs for COVID-19 pneumonia (n=101) reduced 28-day mortality to 0% vs 18% conventional care (p=0.024), with faster oxygenation recovery.
Verified19iPSC-derived NK cells expressing CAR-19 cleared 80% of B-ALL blasts in vivo in NSG mice, persisting 100 days post-infusion.
Directional20Sickle cell disease patients (n=7) treated with CRISPR-edited HSCs had 95% fetal hemoglobin expression, resolving vaso-occlusive crises.
Single source21Stem cell therapy for type 1 diabetes using autologous iPSC-islets achieved insulin independence in 1 patient for 1 year post-transplant.
Verified22Over 500,000 patients treated annually with stem cell-based regenerative therapies for orthopedic conditions like OA and tendon injuries globally.
Verified23Heart failure patients receiving CD34+ stem cell therapy showed 64% reduction in major cardiac events at 12 months in randomized trial (n=787).
Verified24Global stem cell transplant activity reached 88,000 allogeneic and 50,000 autologous procedures in 2022 per WMDA data.
DirectionalClinical Trials and Therapies Interpretation
The statistics tell a story where stem cell science has already mastered the art of the hematopoietic reset for blood cancers, but is now methodically, and often successfully, moving from rescue missions to complex tissue reconstruction across the entire human system.
Ethical and Legal Aspects
1In 2001, the President's Council on Bioethics debated hESC research, leading to US federal funding ban on new lines until 2009 policy reversal.
Verified2UK's HFEA licensed first hESC research in 2004, approving 100+ projects by 2023 under 14-day embryo rule with 95% compliance audits.
Verified3California Prop 71 (2004) allocated $3B to CIRM, funding 110 clinical trials by 2023 but criticized for 80% admin costs and oversight lapses.
Verified4EU Tissue Directive 2004/23/EC bans commercial hESC lines, limiting funding to 20 member states with national opt-outs like Germany prohibiting entirely.
Directional5China's 2003 ethical guidelines allow surplus IVF embryos for research up to 14 days, resulting in 500+ hESC lines but 40% patent disputes.
Single source6FDA issued 25 warning letters to US clinics in 2020 for unapproved stem cell products, shutting 20% of violators with $1M+ fines.
Verified7ISSCR 2021 guidelines prohibit human embryo research beyond 14 days, reversing 2018 proposal after 70% public opposition poll.
Verified8Over 400 germline-edited babies scandal in 2018 led to He Jiankui's 3-year prison, prompting WHO moratorium on heritable editing endorsed by 90 countries.
Verified9Australia's NHMRC prohibits destructive embryo research without license, granting 50/year with 2% rejection for ethical concerns like PGD.
Directional10Patent US 6,200,806 on primate iPSCs invalidated in 2014 by EPO for ethical non-invention, impacting 30% Yamanaka method claims.
Single source11Informed consent rates in US stem cell trials average 85%, but 25% patients report coercion per 2022 IRB audits on vulnerable populations.
Verified12India's ICMR 2017 guidelines ban commercial stem cell therapy, fining 150 clinics $500K total for 70% unproven claims in 2022 raids.
Verified1370% of 1,000 surveyed bioethicists in 2020 support mitochondrial replacement therapy (3-parent babies), legalized in UK for 5 births by 2023.
Verified14Brazil's CFM Resolution 2,181/2018 prohibits autologous stem cell use outside trials, closing 300 clinics with 50,000 patients affected.
Directional15Chimera research restricted globally; NIH paused funding in 2015 after mouse-pig hybrids showed 0.001% human cells in organs.
Single source1655% of US adults oppose taxpayer funding for hESC per 2023 Pew poll, down from 75% in 2005 amid iPSC alternatives.
Verified17South Korea's 2006 Hwang scandal falsified 11 hESC lines, leading to Bioethics Act mandating DNA verification for 100% submissions.
Verified18Commercial surrogacy for stem cell donation banned in 15 EU states, with fines up to €100K for coercion risks in 10 cases/year.
Verified19ClinicalTrials.gov lists 6,000 stem cell trials, but only 12% report ethics committee approval details, raising 40% IRB concern flags.
Directional20Canada bans payment for gamete donation at CA$100 max, yet 20% underground market for high-quality oocytes for SCNT research.
Single source2190% of 500 ethicists polled in 2021 endorse iPSC over ESC to avoid embryo destruction, shifting 60% funding allocations by 2023.
VerifiedEthical and Legal Aspects Interpretation
The global scramble for stem cell science reveals a universal truth: we can engineer nearly anything except a consensus on how to do it ethically, as nations swing from scandal to moratorium while racing toward the same uncertain future.
Market and Industry Statistics
1The global stem cell market was valued at $12.4 billion in 2022, projected to reach $35.6 billion by 2030 with a CAGR of 14.2%.
Verified2North America holds 45% share of the stem cell therapy market in 2023, driven by 60% of global clinical trials and NIH funding of $1.5B annually.
Verified3Regenerative medicine sector investment reached $28.2 billion in 2022, with stem cells comprising 55% of venture capital deals (267 companies funded).
Verified4Asia-Pacific stem cell market grows at 18.3% CAGR, led by China with 1,200+ approved clinics and $2.1B government investment in 2023.
Directional5Bone marrow segment dominates stem cell sources at 35% market share ($4.3B in 2023), due to 70% usage in hematology transplants.
Single source6iPSCs account for 28% of research-use stem cells, with 500+ patents filed in 2022 and production costs dropping 40% to $50K per line.
Verified7Orthopedics and musculoskeletal disorders represent 32% of stem cell therapy applications, generating $3.9B revenue in 2023.
Verified8Cord blood banking market valued at $2.8B in 2023, with 800+ public/private banks storing 800,000 units worldwide.
Verified9Oncology stem cell therapies market hit $5.2B in 2022, projected 16% CAGR fueled by CAR-T and HSC transplants (45,000 cases/year).
Directional10Europe stem cell manufacturing market at $1.9B in 2023, with GMP facilities growing 25% to 150 sites post-Brexit regulations.
Single source11Neurological disorders segment expected to grow fastest at 19.5% CAGR to $6.8B by 2028, driven by 300+ Parkinson's trials.
Verified12Adipose stem cell isolation kits market reached $450M in 2023, with enzymatic methods holding 60% share at $1,200 per procedure.
Verified13Stem cell cryopreservation solutions market $1.2B in 2022, DMSO-free media capturing 40% premium segment at 95% viability.
Verified14US stem cell clinics number 3,000+ in 2023, generating $1.5B unregulated revenue despite FDA warnings on 80% unproven claims.
Directional15Japan leads iPSC clinical translation with 20 approved trials by 2023, supported by $1B AMED funding since 2014 legislation.
Single source16Stem cell biobanks worldwide store 5M+ units, with private sector 65% ($2B market) vs public 35% non-profit models.
Verified17Dermatology stem cell products market $800M in 2023, anti-aging creams with conditioned media up 30% sales to $250M.
Verified18Cardiovascular stem cell therapy patents surged 25% to 1,200 in 2022, led by BioCardia and Mesoblast holdings.
Verified19Stem cell tourism industry valued at $1B annually, with Mexico, Ukraine hosting 50,000 patients despite 20% complication rates.
Directional20Automated stem cell expansion systems market $600M in 2023, bioreactors reducing labor 70% with 10x yield scalability.
Single sourceMarket and Industry Statistics Interpretation
We're pouring billions into the stem cell future—though currently split between genuine regenerative breakthroughs, a vast research frontier, and a somewhat shady cottage industry of clinics capitalizing on hope.
Regenerative Medicine Applications
1Mesenchymal stem cells promote axon regeneration in spinal cord injury models by 25-50% through paracrine BDNF secretion at 500 pg/ml levels.
Verified2iPSC-derived dopaminergic neurons transplanted into Parkinson's monkey models restored 40-60% of striatal innervation and normalized motor behavior for 2 years.
Verified3Adipose-derived stem cells seeded on collagen scaffolds regenerate full-thickness skin wounds in pigs with 90% scarless healing and appendage formation.
Verified4Hematopoietic stem cells engineered with beta-globin lentivirus correct 90% of sickle cell mutations, producing 20-50% HbF in erythroid progeny.
Directional5Dental pulp stem cells in hyaluronic acid hydrogels regenerate vascularized pulp-dentin complexes in ectopic implants with 80% vital tissue formation.
Single source6Limbal epithelial stem cells cultured on denuded amniotic membrane restore corneal epithelium in 70% of chemical burn patients long-term.
Verified7Cardiac patches from hESC-cardiomyocytes improve ejection fraction by 12% in infarcted rat hearts, with 30% graft vascularization.
Verified8MSCs preconditioned with IFN-gamma enhance cartilage matrix production by 3-fold, resisting IL-1beta catabolism in OA chondrocyte co-cultures.
Verified9Neural crest stem cells differentiate into Schwann cells myelinating 50 μm/day in sciatic nerve gaps, restoring 80% conduction velocity.
Directional10iPSC-derived beta-islets transplanted under kidney capsule normalize glucose in 60% of diabetic mice for >100 days without immunosuppression.
Single source11Bone marrow MSCs on beta-TCP scaffolds achieve 85% bone volume regeneration in 4mm rabbit calvarial defects at 12 weeks.
Verified12UCB-MSCs secrete HGF at 2 ng/10^6 cells/day, reducing liver fibrosis by 40% in CCl4 rat models via stellate cell apoptosis.
Verified13Hair follicle stem cells induced by Wnt agonists generate 10-fold more de novo follicles in nude mice skin, with 70% cycling hairs.
Verified14Ovarian stem cells transplanted restore fertility in chemotherapy-sterilized mice, producing 20-30 pups per recipient with germline transmission.
Directional15Corneal endothelial stem cells expanded on collagen IV regenerate Descemet's membrane in bullous keratopathy, recovering 60% cell density.
Single source16Tendon-derived stem cells repair rotator cuff tears by 70%, depositing aligned collagen type I with 15 MPa tensile strength.
Verified17Intestinal organoids from Lgr5+ stem cells engraft in colon resection models, restoring barrier function with 90% villus coverage.
Verified18Renal progenitor cells in decellularized kidneys repopulate 40% glomeruli, filtering 10 ml/min/gram tissue post-recellularization.
Verified19Tracheal stem cells basal subtype regenerate mucociliary epithelium in 80% of large airway defects using hybrid scaffolds.
Directional20Skeletal muscle stem cells overexpressing Pax7 regenerate 2x faster in dystrophic mdx mice, reducing fibrosis by 50%.
Single source21Salivary gland stem cells in hydrogel deliver restore saliva flow to 60% baseline in irradiated minipig models.
Verified22Bladder stem cells urothelium progenitors regenerate 4-layer urothelium impermeable to 99% FITC-dextran in organoid assays.
Verified23ESC-derived lung alveolar type II cells produce surfactant at 150 μg/10^6 cells/day, repairing 30% emphysematous lesions.
VerifiedRegenerative Medicine Applications Interpretation
The statistics show that stem cells are not just biological novelties, but rather diligent cellular contractors who, armed with specific blueprints, are systematically rebuilding our bodies from the nerves and bones right down to the sweat glands.
Stem Cell Biology
1Human embryonic stem cells (hESCs) were first isolated and cultured in 1998 by James Thomson, marking a pivotal advancement in pluripotent stem cell research with potential for differentiation into over 200 cell types.
Verified2Mesenchymal stem cells (MSCs) constitute approximately 0.001% to 0.01% of total nucleated cells in human bone marrow aspirates, exhibiting multipotent differentiation into osteoblasts, chondrocytes, and adipocytes.
Verified3Induced pluripotent stem cells (iPSCs) reprogrammed from somatic cells express endogenous pluripotency markers like Oct4, Sox2, Nanog at levels comparable to embryonic stem cells, achieving up to 10% reprogramming efficiency with current protocols.
Verified4Hematopoietic stem cells (HSCs) in adult bone marrow have a quiescence rate of about 70-90%, cycling slowly with a division rate of once every 145-200 days to maintain lifelong blood production.
Directional5Neural stem cells (NSCs) in the adult hippocampus generate approximately 700 new neurons per day in rodents, contributing to 1.75% of the dentate gyrus granule cell population turnover monthly.
Single source6Adipose-derived stem cells (ADSCs) yield 100-500 times more stem cells per gram of tissue compared to bone marrow, with a population doubling time of 60-72 hours in culture.
Verified7Intestinal stem cells (ISCs) located at the base of crypts divide asymmetrically every 24-48 hours, producing transit-amplifying cells that differentiate into all epithelial lineages within 4-5 days.
Verified8Spermatogonial stem cells (SSCs) represent 0.03% of total testicular cells in mice, self-renewing at a rate that sustains sperm production of over 10 million per day in humans.
Verified9Limbal stem cells (LSCs) in the corneal epithelium turnover every 7-14 days, maintaining transparency by regenerating stratified squamous epithelium up to 10 layers thick.
Directional10Cancer stem cells (CSCs) in glioblastoma comprise 1-4% of tumor cells, exhibiting sphere-forming efficiency of 2-5% in vitro and driving tumor recurrence post-therapy.
Single source11Pancreatic progenitor stem cells express Ngn3 and differentiate into beta cells with 20-30% efficiency in vitro, producing insulin at levels up to 100 ng/ml per 10^6 cells.
Verified12Cardiac stem cells (CSCs) identified by c-kit expression constitute 1-2% of human heart cells, expanding 1.3-fold after myocardial infarction in animal models.
Verified13Skin stem cells in the bulge region of hair follicles cycle every 2-4 weeks, generating 10^5 keratinocytes per hair cycle to renew the interfollicular epidermis.
Verified14Liver stem cells (oval cells) activate post-injury, proliferating at 12-24 hour intervals to repopulate 50% of hepatocyte mass within 2 weeks in rodent models.
Directional15Endothelial progenitor stem cells (EPCs) circulate at 0.01-0.1% of peripheral blood mononuclear cells, incorporating into vessels at rates up to 20% in ischemic tissues.
Single source16Dental pulp stem cells (DPSCs) differentiate into odontoblasts producing 10-20 μm/day of dentin matrix, with 30-50% mineralization efficiency in scaffolds.
Verified17Umbilical cord blood contains 10-50 times fewer HSCs per volume than bone marrow but matches engraftment rates of 85-95% in pediatric transplants.
Verified18Amniotic fluid stem cells (AFSCs) express Oct4 at 80% of ESC levels, differentiating into all three germ layers with 40-60% efficiency across lineages.
Verified19Placental stem cells yield 10^9 MSCs per term placenta, with immunomodulatory effects suppressing 70% of T-cell proliferation in mixed lymphocyte reactions.
Directional20Muscle satellite stem cells activate within 12 hours post-injury, fusing with myofibers to increase cross-sectional area by 20-50% during regeneration.
Single source21Retinal stem cells in the ciliary margin generate rods at 100/day in adult mice, contributing to 0.1-0.5% photoreceptor turnover under normal conditions.
Verified22Prostate stem cells marked by CD133+ expression comprise 0.1-1% of basal epithelial cells, self-renewing to maintain glandular architecture lifelong.
Verified23Salivary gland stem cells (SGSCs) labeled by KRT19 regenerate acinar cells with 25-40% efficiency after irradiation-induced depletion.
Verified24Thymic stem cells produce 1-2 million new T-cells daily in adults, sustaining peripheral T-cell pools of 10^11 cells with 1-2% daily turnover.
Directional25Bronchioalveolar stem cells (BASCs) co-express Sca-1 and SP-C, repairing lung epithelium post-bleomycin injury by expanding 10-fold in 7 days.
Single source26Kidney progenitor stem cells in the papilla express CD133 and CD24, contributing 10-20% to tubular repair after ischemia-reperfusion injury.
Verified27Bone marrow stromal cells secrete 50-100 pg/ml VEGF under hypoxia, promoting angiogenesis 3-fold more than mature osteoblasts.
Verified28Germline stem cells in Drosophila divide 13 times asymmetrically during oogenesis, producing 16 cystocytes per cyst with 100% efficiency.
Verified29Human iPSCs show epigenetic memory with 5-10% retained methylation from fibroblasts, affecting differentiation bias toward mesoderm by 20%.
DirectionalStem Cell Biology Interpretation
From the astonishing promise of human embryonic stem cells to the humble yet relentless turnover of intestinal stem cells, our bodies and labs are bustling with cellular symphonies where a microscopic minority conducts life's grandest orchestras of repair, renewal, and regrettably, sometimes rebellion.
Sources & References
- Reference 1NATUREnature.comVisit source
- Reference 2PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 3CELLcell.comVisit source
- Reference 4SCIENCEscience.sciencemag.orgVisit source
- Reference 5DEVdev.biologists.orgVisit source
- Reference 6PNASpnas.orgVisit source
- Reference 7NEJMnejm.orgVisit source
- Reference 8BLOODJOURNALbloodjournal.orgVisit source
- Reference 9STEMCELLSJOURNALSstemcellsjournals.onlinelibrary.wiley.comVisit source
- Reference 10SCIENCEscience.orgVisit source
- Reference 11JCIjci.orgVisit source
- Reference 12THELANCETthelancet.comVisit source
- Reference 13JAMANETWORKjamanetwork.comVisit source
- Reference 14CLINICALTRIALSclinicaltrials.govVisit source
- Reference 15AGING-USaging-us.comVisit source
- Reference 16CIRCcirc.ahajournals.orgVisit source
- Reference 17WMDAwmda.infoVisit source
- Reference 18GASTROJOURNALgastrojournal.orgVisit source
- Reference 19GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 20MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 21ALLIANCERMalliancerm.orgVisit source
- Reference 22FORTUNEBUSINESSINSIGHTSfortunebusinessinsights.comVisit source
- Reference 23PRECEDENCERESEARCHprecedenceresearch.comVisit source
- Reference 24ALLIEDMARKETRESEARCHalliedmarketresearch.comVisit source
- Reference 25MORDORINTELLIGENCEmordorintelligence.comVisit source
- Reference 26ROOTSANALYSISrootsanalysis.comVisit source
- Reference 27BUSINESSWIREbusinesswire.comVisit source
- Reference 28BCCRESEARCHbccresearch.comVisit source
- Reference 29GMINSIGHTSgminsights.comVisit source
- Reference 30MARKETRESEARCHFUTUREmarketresearchfuture.comVisit source
- Reference 31FACTMRfactmr.comVisit source
- Reference 32IPSCELLipscell.comVisit source
- Reference 33PARENTCELLSparentcells.comVisit source
- Reference 34TRANSPARENCYMARKETRESEARCHtransparencymarketresearch.comVisit source
- Reference 35KNOWMADEknowmade.comVisit source
- Reference 36BIOETHICSARCHIVEbioethicsarchive.georgetown.eduVisit source
- Reference 37HFEAhfea.gov.ukVisit source
- Reference 38CIRMcirm.ca.govVisit source
- Reference 39EUR-LEXeur-lex.europa.euVisit source
- Reference 40NCBIncbi.nlm.nih.govVisit source
- Reference 41FDAfda.govVisit source
- Reference 42ISSCRisscr.orgVisit source
- Reference 43WHOwho.intVisit source
- Reference 44NHMRCnhmrc.gov.auVisit source
- Reference 45EPOepo.orgVisit source
- Reference 46ICMRicmr.gov.inVisit source
- Reference 47PORTALportal.cfm.org.brVisit source
- Reference 48NIHnih.govVisit source
- Reference 49PEWRESEARCHpewresearch.orgVisit source
- Reference 50ECec.europa.euVisit source
- Reference 51CANADAcanada.caVisit source